Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

5.0K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.0K
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
Renewal of Intestinal Stem Cells01:23

Renewal of Intestinal Stem Cells

2.7K
The intestinal epithelial lining rapidly renews every 4 to 5 days. The renewal is facilitated by intestinal stem cells (ISCs) located at the base of the crypt– a gland located at the bottom of each villus. ISCs divide asymmetrically to form new stem cells and progenitor daughter cells. The daughter cells are called transit-amplifying (TA) cells which move upwards along the crypt and either differentiate into absorptive cells– the enterocytes or secretory cells– including the...
2.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ATG Exposure in T Replete Transplant for Hematological Malignancies: Real World Analysis from BMT CTN 1202.

Research square·2026
Same author

Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.

Blood immunology & cellular therapy·2026
Same author

Differential effects of GVHD therapies on intestinal epithelium.

Blood advances·2026
Same author

AML biology matters, so should we transplant ASAP?

Blood·2025
Same author

Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity.

Transplantation and cellular therapy·2025
Same author

Soluble urokinase plasminogen activator receptor and acute kidney injury in hematopoietic cell transplantation.

Blood advances·2025

Related Experiment Video

Updated: Sep 10, 2025

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.3K

Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD.

Aaron M Etra1, James L M Ferrara1, John E Levine1

  • 1Division of Hematology/Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

Blood
|August 22, 2025
PubMed
Summary

The U.S. FDA approved remestemcel-L (Ryoncil) for pediatric steroid-refractory acute graft-versus-host disease (SR-aGVHD). This new therapy shows promising response and survival rates in young patients.

More Related Videos

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

4.7K
Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
11:37

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

6.7K

Related Experiment Videos

Last Updated: Sep 10, 2025

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.3K
Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

4.7K
Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
11:37

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

6.7K

Area of Science:

  • Hematology
  • Immunology
  • Cell Therapy

Background:

  • Steroid-refractory acute graft-versus-host disease (SR-aGVHD) is a serious complication following stem cell transplantation.
  • Ruxolitinib (Jakafi) was the sole FDA-approved therapy for SR-aGVHD in patients over 12 years old.
  • Limited treatment options exist for pediatric patients with SR-aGVHD.

Purpose of the Study:

  • To highlight the recent U.S. FDA approval of remestemcel-L (Ryoncil) for pediatric SR-aGVHD.
  • To present the efficacy of remestemcel-L in this patient population.

Main Methods:

  • Review of the FDA approval and clinical data for remestemcel-L.
  • Focus on outcomes in pediatric patients (18 years and younger) with SR-aGVHD.

Main Results:

  • Remestemcel-L (Ryoncil) has received FDA approval for pediatric patients (≤18 years) with SR-aGVHD.
  • Clinical data indicate a 70% response rate with remestemcel-L treatment.
  • Nearly 70% six-month survival rates were observed in treated pediatric patients.

Conclusions:

  • Remestemcel-L represents a significant therapeutic advance for pediatric SR-aGVHD.
  • The approval offers a new, effective treatment option for a vulnerable patient group.
  • This development addresses a critical unmet need in pediatric stem cell transplantation.